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A TRIP THROUGH EMPLOYMENT LAW: PROTECTING
THERAPEUTIC PSILOCYBIN USERS IN THE WORKPLACE
Ben Sheppard1
Abstract
In 2020, Oregon voters legalized therapeutic psilocybin. Oregon voters
legalized therapeutic psilocybin in response to a plethora of scientific studies
showing symptom reduction for depression, anxiety, substance use disorders,
opioid addictions, migraines, and other mental illnesses, HIV/AIDS, and cancer.
The legal rethinking regarding therapeutic psilocybin continues in both state
legislatures and city councils. Yet, despite state and local legalization or
decriminalization of therapeutic psilocybin it remains illegal under the federal
Controlled Substances Act. This tension between local and federal law places
therapeutic psilocybin users and their employers in a difficult position. Because
all types of psilocybin use remain illegal under federal law, a zero-tolerance drug
use workplace policy would discipline a state sanctioned psilocybin user for offsite or off-hours therapeutic psilocybin use. Therefore, this article proposes that
as states and cities legalize therapeutic psilocybin, jurisdictions should adopt
employment protections for therapeutic psilocybin users like states have adopted
for medical cannabis users. The proposed statute in this article protects
therapeutic psilocybin users from adverse action based solely on off-site and offhours drug use and balances employers’ rights.

1 Benjamin

Sheppard is a judicial law clerk for the Honorable Stephen G. Baratta of the
Northampton County Court of Common Pleas. The author earned his J.D. from the George
Washington University Law School. The author would like to thank Professor Naomi
Schoenbaum and Mike Moberly for their thoughtful comments and insights. The views expressed
in this article are personal to the author and do not necessarily represent the views of their
employer.
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INTRODUCTION
Imagine losing your job because of medicine prescribed to you by your
doctor. This is the situation Rojerio Garcia, who suffered from HIV/AIDS found
himself in after he was hired at a new job.2 Soon after his hiring, he was subjected
to a random drug test and tested positive for psilocybin metabolites.3 Garcia
explained to his employer he used psilocybin to treat his HIV/AIDS.4
Nonetheless, the employer discharged him anyways because the federal
Controlled Substances Act (“CSA”) prohibits all forms of psilocybin use.5
In response, Garcia sued and argued his employer unlawfully terminated
him for his state-sanctioned therapeutic6 psilocybin use.7 The US District Court
for New Mexico held the employer did not engage in employment discrimination
because the state mandated no statutory duty to accommodate psilocybin use and
it did not fire Garcia on the basis of his disability but instead based on his
federally illegal psilocybin use.8
Unfortunately, Mr. Garcia is not the only individual fired based on
therapeutic or medical drug use. At least six different courts have held without a

2

See Garcia v. Tractor Supply Co., 154 F.Supp.3d 1225, 1226-27 (D.N.M. 2016). A small-scale
study showed psilocybin improves symptoms associated with HIV/AIDS. Brian T. Anderson,
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An openlabel safety and feasibility pilot study, LANCET,
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)302820/fulltext?fbclid=IwAR0_ldjHcMzVmMqpGkzRVVDHsiOmDv7vYw7bXgMbWDpFBM0XSay
Vxbq7dI4.
3 I changed the drug (originally medical cannabis) to psilocybin to demonstrate employers often
take adverse action against employees who use state sanctioned medical drugs that are federally
illegal. See Garcia, 154 F.Supp.3d at 1227. A small 2002 urinalysis study detected psilocybin
twenty-four hours after use. Felix Hasler et al., Renal excretion profiles of psilocin following oral
administration of psilocybin: a controlled study in man, J. PHARM. BIOMED ANAL. (Sep. 2002),
https://pubmed.ncbi.nlm.nih.gov/12191719/ Tests of hair samples can detect psilocybin ninety
days after use. Alan Carter & Adrienne Santos-Longhurst, Will Mushrooms Show Up on a Drug
Test?, HEALTHLINE (Jan. 23, 2020), https://www.healthline.com/health/do-shrooms-show-up-on-adrug-test#urine-test.
4 Garcia, 154 F.Supp.3d at 1227.
5 See generally id. at 1229-30.
6 Therapeutic psilocybin differs from the term medical/medical psilocybin. Therapeutic means a
drug can only be provided and administered in licensed facilities. Terry Nguyen, How mushrooms
took over food, wellness, and (of course) drugs, VOX (Apr. 9, 2021), https://www.vox.com/thegoods/22372504/mushrooms-food-wellness-drugs; Robert A. Mikos, We Need A Cole
Memorandum for Magic Mushrooms, 2021 U. ILL. L. REV. ONLINE 87, 91-92 (2021) (explaining
Oregon policies concerning therapeutic psilocybin). By contrast, medical/medical means the drug
may be bought at a facility and consumed/ingested/smoked off-site. See David J. Cohen, Medical
Marijuana in Pennsylvania, DAVID J. COHEN LAW FIRM, LLC,
https://www.davidcohenlawfirm.com/medical-marijuana#.
7 Garcia, 154 F.Supp.3d at 1226.
8 Id. at 1226-29.
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statutory duty to accommodate drug use (e.g., cannabis9 or psilocybin) an
employer may take adverse action for off-site and off-hours federally illegal drug
use despite legalization at the state level.10 Courts are reluctant to enforce existing
state employment protections for individuals who use drugs deemed unlawful by
the CSA but legal under their state’s law.11 Additionally, many employees suffer
adverse employment action for using federally illegal drugs each year despite
9

In this paper, I use the term “cannabis” as much as possible, both because of the racist origins of
“marijuana” in prohibition campaigns and the more positive connotation “cannabis” has compared
to marijuana. Alex Halperin, Marijuana: Is It Time to Stop Using a Word with Racist Roots?, THE
GUARDIAN (Jan. 29, 2018), https://www.theguardian.com/society/2018/jan/29/marijuana-namecannabis-racism; Daniel G. Orenstein & Stanton; A. Glantz, Cannabis Legalization in State
Legislatures: Public Health Opportunity and Risk, 103 MARQ. L. REV. 1313, 1315 n.1 (2020);
Sean M. O’Connor & Erika Leitzan, The Surprising Reach of FDA Regulation of Cannabis, Even
After Descheduling, 68 AM. U. L. REV. 823, 834 (2019). Where context requires, I use the terms
“marijuana” and it should be considered synonymous with “cannabis.” Other commentators have
written about racist “marijuana” prohibition campaigns. E.g. Michael Vitiello, Marijuana
Legalization, Racial Disparity, and the Hope for Reform, 23 LEWIS & CLARK L. REV. 789, 791809 (2019).
10 See Brian P. Sharkey & David L. Disler, Are New Jersey Law Firms Prepared for the
Legalization of Marijuana?, N.J. LAW., 32, 33 n.5 (October 2018) (collecting cases); Garcia, 154
F.Supp.3d 1125; Coats v. Dish Network, LLC, 350 P.3d 849, 853 (Colo. 2015); Casias v. WalMart Stores, Inc., 764 F. Supp. 2d. 914, 924 (W.D. Mich. 2011) (“Michigan voters could not have
intended to enact private employment regulation implicitly, through a negative inference, when the
rights of employees are never mentioned anywhere else in the statute.”), aff'd, 695 F.3d 428 (6th
Cir. 2012); Roe v. TeleTech Customer Care Mgmt. (Colorado) LLC., 257 P.3d 586 (Wash. 2011)
(“The language of the law is unambiguous it does not regulate the conduct of a private employer
or protect an employee from being discharged because of authorized medical marijuana use.”);
Emerald Steel Fabricators Inc. v. Bureau of Lab. and Indus., 230 P.3d 518, 536 (Or. 2010);
Johnson v. Columbia Falls Aluminum Co., LLC, 350 Mont. 562 (2009); Ross v. Raging Wire
Telecommunications Inc., 174 P.3d 200 (Cal. 2008); Judge Mary A. Celeste & Melia ThompsonDudiak, Has the Marijuana Classification Under the Controlled Substances Act Outlived Its
Definition?, 20 CONN. PUB. INT. L.J. 18, 29 (2020) (“Thus, absent a veil of a statutory or other
legal nuance, such as anti-discrimination provisions, courts pressed to decide issues directly
involving marijuana seem to adhere to the federal government’s fixed stance.”); Adam J. Agostini,
Marijuana Legalization and Employee-Employer Rights: An All-Time High for Non-Uniformity,
35 ABA J. LAB. & EMP. L. 183, 193 (2020) (“[C]ourts will generally defer to federal law and the
CSA's classification of marijuana to find in favor of employers where the state legislature has
remained statutorily silent as to off-duty marijuana usage.”). American employment is generally
employment-at-will and therefore an employer does not need a reason to terminate. Kelcey
Phillips, Employees Getting Lost in the Trees: Tameny Claims and the Public Policy Behind
Preventing Termination on the Basis of Medical Marijuana Use, 52 U.S.F. L. REV. 115, 124
(2018); E.g. Gibbs v. Allen’s Fam. Foods, No. CIV.A. S11A-06-004, 2012 WL 5830697 * at 3
(Del. Super. Ct. Apr. 25, 2012) (firing at-will-employee for cannabis use).
11 Ruth Rauls, Workplace Marijuana Accommodations: The Road Ahead, LAW360 (May 19,
2017, 11:41 AM), https://www.law360.com/articles/922194/workplace-marijuanaaccommodations-the-road-ahead; Joshua Weisenfeld, Medical Marijuana Patients:
Discrimination & the Search for Employment Protections, 27 CARDOZO J. EQUAL RTS. & SOC.
JUST. 375, 397 (2021) (“[U]nless a state’s legislature had the foresight to include employment
protections in their medical marijuana statutes, employment protections are still unavailable to
medical marijuana patients for adverse employment decisions on the basis of their medical
marijuana use.”).
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states legalizing medical or therapeutic drug use.12 Thirty-six states, the District of
Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands have legalized medical
cannabis13 but only seventeen provide users statutory employment protections.14
But this legal rethinking continues with other drugs. In 2020, Oregon
became the first US jurisdiction to legalize therapeutic psilocybin use.15 Oregon
law permits licensed providers to administer therapeutic psilocybin to individuals
over twenty-one.16 State regulators have two years to work out regulatory details
regarding therapeutic psilocybin practices.17 In addition, legislators in California,
Connecticut, Florida, Hawaii, Iowa, Kansas, Missouri, New York, Washington,
and Virginia are debating psilocybin reform bills during their current legislative

12 E.g.

Jennifer McLogan, Long Island Woman Sues Home Depot, Says She Was Denied Job Due
to Having Medical Marijuana Card, CBS NEW YORK (Apr. 22, 2021),
https://newyork.cbslocal.com/2021/04/22/medical-marijuana-card-lawsuit-home-depot-felitadobbins/; THE ASSOCIATED PRESS, Florida city fires employee over legal medical marijuana use,
ABC NEWS (Mar. 26, 2021), https://abcnews.go.com/Health/wireStory/florida-city-firesemployee-legal-medical-marijuana-76702772; Jessica Kwong, Teacher who tested positive for
medical weed after being assaulted by student is fired, METRO (Mar. 26, 2021),
https://metro.co.uk/2021/03/26/teacher-shoved-on-stairway-by-student-fired-for-medicalmarijuana-use-14312450/; Dan Hyman, When the Law Says Using Marijuana Is O.K., but the
Boss Disagrees, N.Y. TIMES (Jul. 19, 2019),
https://www.nytimes.com/2019/07/19/business/marijuana-employer-drug-tests.html (“I will tell
[California] companies frankly and honestly that I will fail the [drug test for medical cannabis]…
And that’s usually when the interview ends.”).
13 Alex C. Carroll, Weed, Dogs & Traffic Stops, 21 WYO. L. REV. 1, 4 (2021). While not discussed
in this article seventeen states and the District of Columbia have legalized recreational cannabis
use. State v. Junjie Li, Nos. K2-2019-0513A, K2-2019-0513B, 2021 R.I. Super. LEXIS 41 * at 1
(Super. Ct. May 10, 2021). Currently, a law to permit recreational cannabis use in South Dakota is
being litigated in the state’s courts. Stephen Groves, South Dakota Supreme Court weighs pot
legalization battle, ABC NEWS (Apr. 28, 2021), https://abcnews.go.com/Health/wireStory/southdakota-supreme-court-weighs-pot-legalization-battle-77375674.
14 See Sachi Barreiro, State Laws on Off-Duty Marijuana Use, NOLO (2021),
https://www.nolo.com/legal-encyclopedia/state-laws-on-off-duty-marijuana-use.html; John I.
Winn, When the Going Gets Weird, the Weird Turn Pro: Management Best Practices in the Age of
Medical Marijuana, 25 ROGER WILLIAMS U. L. REV. 60, 61 n.5 (2020) (listing all states except
recent Virginia and South Dakota legislation); V.A. Code § 54.1-3408.3 (2021); S.D. CODIFIED
LAWS § 34-20G-22 (2021).
15 Stephanie Zimmermann, Successful Ballot Measures for Marijuana and Other Substances
Create Opportunities for Lawyers, ABA J. at 16 (Feb. 1, 2021, 1:30 AM). Additionally, Oregon
voters reclassified the possession of cocaine, heroin, methamphetamine, or oxycodone from a
Class A misdemeanor to a Class E violation, punishable by only a $ 100 dollar fine. Id. Thomas
Firestone, The Future of Drug Decriminalization After Oregon, LAW360 (Dec. 16, 2020, 3:52
PM), https://www.law360.com/articles/1338128/the-future-of-drug-decriminalization-afteroregon.
16 Nicholas Ansel, Advancing Criminal Reform Through Ballot Initiatives, 53 ARIZ. ST. L.J. 273,
320 (2021).
17 Lizzy Acker, Oregon becomes first state to legalize psychedelic mushrooms, THE OREGONIAN
(Nov. 04 2020, 8:26 PM), https://www.oregonlive.com/politics/2020/11/oregon-becomes-firststate-to-legalize-psychedelic-mushrooms.html
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sessions.18 States are rethinking psilocybin regulation in response to scientific
studies showing it is an effective treatment for depression, anxiety, substance use
disorders, opioid addictions, migraines, and other mental illnesses.19
Despite psilocybin providing users with therapeutic benefits, individuals
may fear discrimination from their employer based on their state sanctioned
psilocybin use. Employers tend to fear what they do not understand,20 both
psilocybin and mental illness are misunderstood in American society.21 Research
shows that employers are less likely to hire individuals with mental illnesses than
those with physical disabilities.22 Without statutory employment protections
regarding therapeutic psilocybin use, patients may hesitate to participate in such
programs out of fear of losing employment.23 If jurisdictions are willing to permit
the use of therapeutic psilocybin, they should not force citizens to choose between
their health and employment. State protections like those instituted for medical
cannabis users could shield patients from employment discrimination solely based
on off-site and off-hours therapeutic psilocybin use.24 This paper recommends

18 Ben

Adlin, DEA Sued by Doctor Who Wants Permission to Give Psilocybin Mushrooms to
Patients, MARIJUANA MOMENT (Mar. 10, 2021), https://www.marijuanamoment.net/dea-sued-bytherapists-who-want-permission-to-give-psilocybin-mushrooms-to-patients/.
19 See generally, Dustin Marlan, Beyond Cannabis: Psychedelic Decriminalization and Social
Justice, 23 LEWIS & CLARK L. REV. 851, 873-74 (2019); Eric W. Dolan, A single dose of
psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebocontrolled study, PSYPOST (May 18, 2021), https://www.psypost.org/2021/05/a-single-dose-ofpsilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebocontrolled-study-60793. Investors such as Shark Tank’s Kevin O’Leary are increasingly bullish
regarding psychedelic investments. Eric Rosenbaum, ‘Shark Tank’ host Kevin O’Leary:
Psychedelic drugs ‘far exceed’ cannabis investment potential, CNBC (May 12, 2021),
https://www.cnbc.com/2021/05/11/kevin-oleary-psychedelic-drugs-far-exceed-cannabispotential.html.
20 Elisa Y. Lee, An American Way of Life: Prescription Drug Use in the Modern ADA Workplace,
45 COLUM. J.L. & SOC. PROBS. 303, 352 (2011).
21 Mason Marks, Psychedelic Medicine for Mental Illness and Substance Use Disorders:
Overcoming Social and Legal Obstacles, 21 N.Y.U. J. LEGIS. & PUB. POL’Y 69, 96 (2018)
[hereinafter Marks I]
22 See, e.g., Song Ju et al., Employer Attitudes Toward Workers with Disabilities: A Review of
Research in the Past Decade, J. VOCATIONAL REHABILITATION 113, 119 (2013).
23 Marks I, supra note 21 at 132-33; See also Paul E. Cirner, New Measures in Oregon
Decriminalize Certain Narcotics and Legalize Psilocybin Therapy, OGELTREE DEAKINS (Nov. 18,
2020), https://ogletree.com/insights/new-measures-in-oregon-decriminalize-certain-narcotics-andlegalize-psilocybin-therapy/. (“[Oregon’s therapeutic psilocybin law does] not impact an Oregon
employer’s drug testing or drug-free workplace practices… [it does not require] an employer to
tolerate on-the-job drug possession, reporting to work impaired, or continued employment of an
individual who violates an employer’s legally compliant drug testing or drug-free workplace
policies.”); Michael D. Moberly, Weeding Out Risky Employees Little Guidance for Arizona in
Landmark Medical Marijuana Ruling, ARIZ. ATT’Y, (June 1, 2016) at 38 (illustrating the
distinction between states that provide employment protections for medical cannabis users and
those that do not).
24 Marks I, supra note 21 at 133.
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states enact employment protections for therapeutic psilocybin users in tandem
with state level legalization.
This paper proceeds in three Parts. Part I provides background on
psilocybin’s medical benefits and its governmental regulation. Part II focuses on
state employment protections for drug users and concludes such statutes are likely
not preempted by the CSA. Part III proposes a statute that protects employees
from wrongful termination solely because of their therapeutic psilocybin use.
I.

A MICRODOSE OF PSILOCYBIN

This section introduces the reader to psilocybin. It begins with a
discussion on how psilocybin works and its therapeutic applications for mental
illnesses. This section then surveys the federal, state, and local regulations
regarding psilocybin.
A. WHAT IS PSILOCYBIN?
Psilocybin is the main psychoactive component of hallucinogenic
mushrooms.25 Hallucinogenic mushrooms were used by indigenous people for
thousands of years primarily for spiritual or religious purposes.26 Psilocybin
entered US public discussion in 1957 when R. Gordon Wasson published an essay
in Life Magazine regarding his experience ingesting hallucinogenic mushrooms in
a Mazatec ritual.27
Psilocybin works as a “serotonin receptor agonist,” by primarily affecting
the brain’s serotonin.28 The effects of psilocybin occur in two distinct stages.
First, shortly after psilocybin is consumed, the user enters an acute psychedelic
state that significantly alters the conscious experience.29 This phase may cause

25 R.R.

Griffiths et al., Psilocybin Occasioned Mystical-Type Experiences: Immediate and
Persisting Dose-Related Effects, 218 J. PSYCHOPHARMACOLOGY 649 (2011).
26 Kathryn L. Tucker, Psychedelic Medicine: Galvanizing Changes in Law and Policy to Allow
Access for Patients Suffering Anxiety Associated with Terminal Illness, 21 QUINNIPIAC HEALTH
L.J. 239, 240 (2018) [Tucker I].
27 Id. at 240.
28 R.L. Carhart-Harris & D.J. Nutt, Serotonin and Brain Function: A Tale of Two Receptors,
J. PSYCHOPHARMACOLOGY (Aug. 31, 2017), https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5606297/; Charles D. Nichols & Elaine Sanders-Bush, Serotonin Receptor Signaling and
Hallucinogenic Drug Action, 2 HEFFTER REV. PSYCHEDELIC RES. 73 (2001),
https://bibliography.maps.org/bibliography/default/resource/5874.
29 James W.B. Elsey, Psychedelic Drug Use in Healthy Individuals: A Review of Benefits, Costs,
and Implications for Drug Policy, DRUG SCI. POL’Y & L., (July 26, 2017) at 2.
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users to feel a sense of unity, ineffability, extreme positivity, transcendence of
time and a feeling of revelation.30 This stage lasts from minutes to hours.31
Second, after the acute psychedelic state, the user often experiences the
“afterglow phase” where they may have an increased positive mood and feel less
preoccupied by worries and stresses.32 This phase usually lasts about two to four
weeks.33 There may be lasting long-term psychological changes such as increased
emotional and brain plasticity caused by psilocybin’s effects or of the subjective
psychedelic experience itself.34
Neuroscience research suggests the aforementioned stages occur because
of significant changes to the brain’s default mode network (“DMN”).35 The DMN
supports cognitive processes such as introspection and contemplation of one’s
past and future.36 Psilocybin consumption promotes an unrestrained style of
thinking by reducing neural activity inside the DMN and creates its mystical
effects.37
B. HOW PSILOCYBIN CAN TREAT MENTAL ILLNESS
Psilocybin has been used as an effective treatment for depression, anxiety,
substance use disorders, opioid addictions, and other mental illnesses.38 Recent
scientific research showed psilocybin rapidly improved symptoms and even
resulted in remission in some cases for patients with major depressive disorders.39
The results of the trial showed psilocybin treatment was associated with a greater
than fifty percent reduction in depressive symptoms in sixty-seven percent of
study participants.40 Additionally, seventy-one percent of participants showed
progress in reducing their major depression at a four-week follow-up.41 A total of

30 Mason M.

Marks, Controlled Substance Regulation for the COVID-19 Mental Health Crisis, 72
ADMIN. L. REV. 649, 685 (2020) [hereinafter Marks II].
31 Elsey, supra note 29 at 2.
32 Id.; Fredrick S. Barrett et al., Emotions and brain function are altered up to one month after a
single high dose of psilocybin, 10 SCIENTIFIC REPORTS 1 (2020).
33 Elsey, supra note 29 at 2.
34 Id.; Barrett et al., supra note 32 at 1.
35 Robert Leech et al., The Entropic Brain: A Theory of Conscious States Informed by
Neuroimaging Research with Psychedelic Drugs, FRONT. HUM. NEUROSCI., 1, 6 (Feb. 2014).
36 Leech et al., supra note 34 at 1,6.
37 Jasmine Virdi, Psychedelics and the Default Mode Network, PSYCHEDELICS TODAY (Feb. 4,
2020), https://psychedelicstoday.com/2020/02/04/psychedelics-and-the-default-mode-network/
38 Marlan, supra note 19 at 873-74.
39 Alan K. Davis et al., Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder,
JAMA PSYCHIATRY (2020).
40 Davis et al., supra note 39 at 33.
41 Id.
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fifty percent of participants achieved remission from their major depression.42
These findings are particularly exciting because psilocybin worked as a treatment
only after a single session or a few sessions and had enduring effects.43 By
contrast, most conventional depression treatments are given frequently and have
chronic side effects.44 However, researchers believe patients who suffer from
decades long depression may require more than one or two psilocybin doses.45
Other related studies support psilocybin uses in depression treatment. In
2016, research showed psilocybin helped treatment resistant major depression
patients.46 In this study, sixty-seven percent of participants showed significant
reductions in symptoms after only one week.47 Another study showed psilocybin
dramatically improved depressive symptoms for cancer patients.48 The panoply
of studies supporting psilocybin as a treatment for depression caused the Food and
Drug Administration (“FDA”) to designate psilocybin a “breakthrough therapy”
for treating major depressive disorder.49
C. Government Regulation of Psilocybin
1. FEDERAL GOVERNMENT REGULATION OF PSILOCYBIN
Despite the FDA deeming psilocybin a breakthrough therapy the CSA
outlaws all uses of psilocybin. Some of the earliest federal regulations concerning
psilocybin were the 1962 Kefauver-Harris Amendments to the 1938 Food, Drug,
and Cosmetics Act.50 The Amendments required detailed and well-controlled
investigations showing that drug was safe and effective before marketing to the
public.51 Under the Amendments, psychedelics could no longer be provided to
42 Id.

Five years later the single dose of psilocybin still showed significant benefits for the patients
in the study. Gabrielle Agin-Liebes, Long-term follow-up of psilocybin-assisted psychotherapy for
psychiatric and existential distress in patients with life-threatening cancer, J. OF
PSYCHOPHARMACOLOGY (2020).
43 Batya Swift Yasgur, Psilocybin Delivers ‘Remarkable’ Relief in Severe Depression, MEDSCAPE
(Nov. 05, 2020), https://www.medscape.com/viewarticle/940477.
44 Id.
45 Zoe Cormier, Psilocybin Therapy May Work as Well as Common Antidepressant, SCIENTIFIC
AMERICAN (Apr. 15, 2021), https://www.scientificamerican.com/article/psilocybin-therapy-maywork-as-well-as-common-antidepressant/.
46 Mark Bolstridge et al., Psilocybin with psychological support for treatment-resistant
depression: an open-label feasibility study, LANCET PSYCHIATRY (2016).
47 Id. at 39.
48 Yasgur, supra note 43. Additional research with more participants is needed regarding
therapeutic psilocybin. Ezra Klein, Can Magic Mushrooms Heal Us?, N.Y. TIMES (Mar. 21,
2021), https://www.nytimes.com/2021/03/18/opinion/oregon-psychedelic-therapy.html.
49 Matt Lamkin, Legitimate Medicine in the Age of Consumerism, 53 U. CAL. DAVIS L. REV. 385,
389-90 (2019).
50 Marlan, supra note 19 at 867; Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780,
780 (1962).
51 Drug Amendments of 1962, 76 Stat. at 781.
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physicians directly by pharmaceutical companies.52 Now psychedelics could only
be supplied after permission from federal or state agencies.53
After the Kefauver-Harris Amendments, the federal government tightened
psilocybin regulation with the Drug Abuse Control Amendments of 1965 that
forbid the sale or manufacture of any drug with a “hallucinogenic effect.”54
However, the Amendments did not criminalize the possession of psilocybin.55
The federal criminalization of psilocybin came at the urging of President
Richard Nixon.56 In 1969, Nixon officially announced the “War on Drugs,” and
claimed “[drug use] afflict[ed] both the body and soul of America.”57
Subsequently, in 1971, President Nixon stated, “America’s public enemy number
one in the United States is drug abuse. In order to fight and defeat this enemy, it is
necessary to wage a new, all-out offensive.”58
Shortly after President Nixon’s declaration, Congress passed the CSA.59
The CSA classifies controlled substances into five schedules based on the
substance’s potential for abuse and its potential for medical uses.60 Psilocybin is
classified as a Schedule I drug, the most severe classification alongside heroin.61
52 Marlan,

supra note 19 at 867.

53 LESTER GRINSPOON & JAMES B. BAKALAR, PSYCHEDELIC DRUGS RECONSIDERED 192

(1997).
Abuse Control Amendments of 1965, 89 Pub. L. No. 74, 79 Stat. 226-28, 230 (1965);
Kathryn L. Tucker, Oregon's Pioneering State Law to Allow Access to Psilocybin, A New
Palliative Care Tool for Patients Suffering Anxiety and Depression, 57 WILLAMETTE L. REV. 13,
17 (2020).
55 Marlan, supra note 19 at 868.
56 See Tucker I, supra note 26 at 242-43.
57 Taylor E. Overman, A “Dubious Distinction”: New Jersey’s Drug-Free School Zones &
Disparately Impacted Minority Communities, 34 B.C. J.L. & SOC. JUST. 397, 401 (2014). In 1994,
John Ehrlichman, one of Nixon’s top advisors, suggested Nixon wage the war on drugs to target
political enemies such as black people and antiwar activists. Courtney Harper Turkington,
Comment, Louisiana’s Addiction to Mass Incarceration by the Numbers, 63 LOY. L. REV. 557,
571, 560-61 (2017); Dan Baum, Legalize It All, HARPER’S MAGAZINE (June 2013),
https://harpers.org/archive/2016/04/legalize-it-all/.
58 President Richard M. Nixon, Remarks About an Intensified Program for Drug Abuse
Prevention and Control, (June 17, 1971), AM. PRESIDENCY PROJECT,
https://www.presidency.ucsb.edu/documents/remarks-about-intensified-program-for-drug-abuseprevention-and-control.
59 See Spencer A. Stone, Note, Federal Drug Sentencing - What Was Congress Smoking? The
Uncertain Distinction Between “Cocaine” and “Cocaine Base” in the Anti-Drug Abuse Act of
1986, 30 W. NEW ENG. L. REV. 297, 309-10 (2007); Dave Rodman, Revisiting the War on Drugs
& Its Impact, THE RODMAN LAW GROUP, LLC (Aug. 8, 2019),
https://therodmanlawgroup.com/revisiting-the-war-on-drugs-its-impact/.
60 21 U.S.C. § 812 (2018).
54 Drug

61 See

Id. Curiously, cocaine is classified as a Schedule II drug despite killing over four thousand
Americans each year. See Keith Humphreys, The Government Still Insists Pot Is More Dangerous
than Cocaine, WASH. POST. (May 15, 2015),
https://www.washingtonpost.com/news/wonk/wp/2015/05/15/why-the-government-still-insistspot-is-more-dangerous-than-cocaine/?utm_term=.9126ca793b1c.
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Despite the previously discussed scientific studies, the federal government by
statutory definition deems psilocybin to have a high risk for abuse and no
recognized medical value. Additionally, as a Schedule I substance, all uses of
psilocybin are illegal under federal law.62 Despite the federal government’s
blanket criminalization of psilocybin, the CSA does not regulate employment
law;63 and does not forbid the employment of a therapeutic psilocybin user.64
2. STATE AND LOCAL LAWS CONCERNING PSILOCYBIN
Despite psilocybin use being illegal under federal law, therapeutic
psilocybin is legal or deemed the lowest criminal enforcement priority in some
jurisdictions. This trend began in May 2019, when Denver, Colorado made
criminal enforcement of its psilocybin statutes the city’s lowest enforcement
priority.65 As of April 2021, seven US cities followed Denver’s lead and made
psilocybin possession law enforcement’s lowest priority.66 In 2020, despite
gathering restrictions created by the COVID-19 pandemic, Oregon activists
submitted enough signatures to place therapeutic psilocybin legalization on the
state’s November ballot.67 It succeeded and Oregon became the first state to
legalize therapeutic psilocybin use.68

62

21 U.S.C. § 844(a) (2018).
SSC Niantic Operating Co. LLC, 273 F. Supp. 3d 326, 336 (D. Conn. 2017).
64 See James v. City of Costa Mesa, 700 F.3d 394, 411-13 (9th Cir. 2012), cert. denied, 133 S. Ct.
2396 (2013); See also Appeal of Panaggio, No. 2019-0685, 2021 WL 787021 * at 8 (N.H. Mar. 2,
2021) (same result); Alexis Gabrielson, The “Right to Use” Takes Its First Hit: Marijuana
Legalization and the Future of Employee Drug Testing, 18 EMP. RTS. & EMP. POL’Y J. 241, 261
(2014).
65 See Marks II, supra note 30 at 669-70. Denver is considering decriminalization of medical
psilocybin and the gifting of psilocybin. Alayna Alvarez, Denver pursues further
decriminalization of magic mushrooms, AXIOS (Apr. 13, 2021), https://www.axios.com/denvermagic-mushrooms-decriminalization-psilocybin-63ffdc19-f2b1-421c-ab09-dcf45559bda4.html.
66 The seven cities are Washington, DC, Oakland, CA, Santa Cruz, CA, Ann Arbor, MI,
Cambridge, MA, Somerville, MA, and Northampton, MA. Allison Margolin, California Climbs
Aboard the Psychedelic Spaceship, MARGOLIN & LAWRENCE,
https://www.margolinlawrence.com/california-climbs-aboard-the-psychedelic-spaceship/; PeterAstrid Kane, The Commodification of Psychedelics, SFWEEKLY (Apr. 15, 2021),
https://www.sfweekly.com/culture/commodification-psychedelics-mushrooms/. Spokane activists
are pursuing legislative action to make psilocybin criminal enforcement law enforcement’s lowest
priority. Casey Decker, Could magic mushrooms be decriminalized in Spokane?, KREM2 (Mar. 16,
2021), https://www.krem.com/article/news/news-explainers/spokane-group-works-todecriminalize-magic-mushrooms/293-10b60c63-cac9-40c3-bb7d-a51c9279f2ff.
67 Tom Angell, Coronavirus Upends Marijuana, Psychedelics And Drug Reform Ballot Measures,
FORBES (Mar. 31, 2020, 10:23 AM),
https://www.forbes.com/sites/tomangell/2020/03/31/coronavirus-upends-marijuana-psychedelicsand-drug-reform-ballot-measures/?sh=7ed8ff2f3645.
68 Will Feuer, Oregon becomes first state to legalize magic mushrooms as more states ease drug
laws in ‘psychedelic renaissance’, CNBC (Nov. 4, 2020, 10:55 AM),
https://www.cnbc.com/2020/11/04/oregon-becomes-first-state-to-legalize-magic-mushrooms-asmore-states-ease-drug-laws.html.
63 Noffsinger v.
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Psilocybin’s legal rethinking continues. Legislators in California,
Connecticut, Florida, Hawaii, Iowa, Kansas, Missouri, New Jersey, New York,
Texas, Washington, Vermont, and Virginia have all considered psilocybin reform
bills.69 On April 6, 2021 a California psilocybin decriminalization bill advanced
through a senate committee by a vote of 4-1.70 The California psilocybin reform
bill is the farthest any state besides Oregon has gone regarding psilocybin reform
this legislative term.71
II.

EMPLOYMENT PROTECTIONS FOR DRUG USERS

Despite psilocybin’s increased acceptance at the state and local level, no
jurisdiction has adopted employment protections for psilocybin users.72 As states
legalize therapeutic psilocybin, they should enact employment protections for
therapeutic psilocybin users just like many states that have enacted employment
protections for medical cannabis users.73 This section begins by surveying the
differing medical cannabis employment protections. Next, the section considers
case law and argues state employment protections for state sanctioned therapeutic
drug users are likely not preempted because the CSA does not include an express
preemption provision, does not intend to occupy the field of illicit drug regulation,
employment protections do not create conflict preemption, and antidiscrimination
statutes regarding drug users do not frustrate the purpose of federal law.74
A. REEFER MADNESS: HAZY STATE EMPLOYMENT PROTECTIONS FOR DRUG USERS
Case law concerning medical cannabis employment protections is helpful
when considering therapeutic psilocybin protections because both drugs are
Schedule I substances under the CSA. Of the thirty-five states that have legalized
medical cannabis only seventeen provide medical cannabis users with some form
69 Adlin,

supra note 18; Sean Neumann, Rick Perry Urges Study Into Using ‘Magic Mushrooms’
to Treat Veterans with PTSD, PEOPLE (Apr. 14, 2021, 3:21 PM), https://people.com/politics/rickperry-urges-texas-to-launch-study-into-using-magic-mushrooms-to-treat-veterans-with-ptsd/; Dom
Amato, Should Vermont decriminalize some hallucinogenic drugs?, WCAX 3 (Jan. 23, 2020, 5:22
PM) (“The bill was read in the [Vermont] House and referred to the [Vermont] Committee on
Judiciary. No word on when it will be discussed next or how far it will go.”),
https://www.wcax.com/content/news/Should-Vermont-decriminalize-some-hallucinogenic-drugs567241491.html. Globally, Austria, Brazil, Czech Republic, Italy, the Netherlands, Portugal, and
Spain decriminalize psilocybin use. Patrick Smith, Magic Mushroom Legality Around the World,
ENTHEONATION https://entheonation.com/blog/magic-mushroom-legality/.
70 See Kyle Jaeger, California Senators Approve Bill To Legalize Possession Of Psychedelics Like
LSD, MDMA And Psilocybin, MARIJUANA MOMENT (Apr. 6, 2021),
https://www.marijuanamoment.net/california-senators-approve-bill-to-legalize-possession-ofpsychedelics-like-lsd-mdma-and-psilocybin/.
71 Id.
72 See Marks I, supra note 21 at 132-33; See also, Cirner, supra note 23.
73 See Iris Hentze, Cannabis & Employment Laws, NATIONAL CONFERENCE OF STATE
LEGISLATURES (Nov. 2, 2020), https://www.ncsl.org/research/labor-and-employment/cannabisemployment-laws.aspx.
74 See infra Sec. II B.
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of statutory employment protections; however, cannabis users enjoy different
levels of employment protections in these various jurisdictions.75 State cannabis
employment protections can be classified into five categories: (1) jurisdictions
requiring an employer make a reasonable accommodation for the employee’s
medical cannabis use, (2) jurisdictions that consider a medical cannabis user
disabled, (3) jurisdictions in which the employee’s underlying medical use and
their status as a cardholder is protected, (4) jurisdiction in which medical cannabis
users must be treated the same as prescription drug users, and (5) jurisdictions
where only an employee’s status as a medical cannabis cardholder is protected.
Nevada is the only jurisdiction that mandates employer’s make a
reasonable accommodation for an employee’s medical cannabis use.76 Under
Nevada law, an employer must make a reasonable accommodation for an
employee’s medical cannabis use so long as it would not (1) pose a “threat” to
persons or property; (2) impose an undue hardship on the employer; and (3)
prohibit the employee from fulfilling their job’s duties.77 Nevada law does not
mandate an employer tolerate an employee’s on-site cannabis use.78
Nevada’s approach to medical cannabis employment protections is unique
in two ways. First, this approach provides medical cannabis users explicit
employment protections.79 Second, the statute’s language requires employers
prove the employee’s medical cannabis use posed a “threat” to the worksite to

75 See

Barreiro, supra note 14. Some commentators have suggested Maryland provides medical
cannabis users employment protections. E.g. Shahabudeen K. Khan, Employers Beware: What Are
Employers’ Obligations and Rights Given New Marijuana Legislations?, 6 BELMONT L. REV. 74,
82 (2019) (“Based on a plain reading of [Maryland’s medical cannabis law], it appears that
employers may be required to accommodate such employees.”). The Maryland law states “[a
qualifying patient] may not be subject to arrest, prosecution, or any civil or administrative penalty,
including a civil penalty or disciplinary action by a professional licensing board, or be denied any
right or privilege, for the medical use of or possession of medical cannabis…” MD. CODE ANN.,
HEALTH-GEN. § 13-3313(a). Arguably, this law could apply to Maryland employers. However, the
Maryland Medical Cannabis Website states: “Maryland law does not prevent an employer from
testing for use of cannabis (for any reason) or taking action against an employee who tests positive
for use of cannabis (for any reason).” Patient FAQ, "My employer tests for drug use including
cannabis. Can they test me if I am a medical cannabis patient? Can they fire me if I use medical
cannabis?" available at http://mmcc.maryland.gov/Pages/patients_faq.aspx (last visited May 30,
2021).
76 Lindsey A. White et al., Smoky Lines: Whether to Accommodate Employees’ Use of Medical
Marijuana May Now Depend on State Law, 68 LAB. L.J. 202, 204 (2017); See also Jayden D.
Gray, Marijuana and the Workplace: How High Are the Stakes for Employees?, 2017 UTAH L.
REV. ONLAW 1, 12-13 (2017).
77 Assemb. B. 533, 2019 Leg., 80th Sess. § 170(3)(a)–(b) (Nev. 2019); Harry Arnold, When Your
Blackjack Dealer Takes a Hit: How Nevada Assembly Bill 132 Threatens Vegas Casinos in an Age
Of Legalized Marijuana, 28 GEO. MASON L. REV. 449, 453 (2020) (“NRS 453A thus affords
employers significant flexibility and deference in the form of various enumerated exceptions for
when accommodations are not required for employees that use medical marijuana.”).
78 Assemb. B. 533, 2019 Leg., 80th Sess. § 170(2) (Nev. 2019).
79 See Khan, supra note 75 at 82.
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justify taking an adverse action.80 By contrast, other statutes use the term
“impairment,” meaning an employer is within its rights in firing an employee
merely showing signs of possible impairment, such as distinct smell or odd
movements, without proving the employee’s cannabis use posed a threat.81
New York follows a similar approach to Nevada but classifies a medical
cannabis patient as being disabled under the New York Human Rights Act.82
Deeming medical cannabis cardholders as automatically disabled means an
employer must accommodate the employee’s disability that necessitates their
cannabis use.83 Like other jurisdictions, New York does not require an employer
tolerate an employee’s on-site cannabis use.84
Arizona, Arkansas, Delaware, Minnesota, New Mexico, Oklahoma, and
Virginia provide employment protections for medical cannabis users based on
their status as cardholders and protection from a positive drug test for cannabis.85
These protections are subject to several exceptions. First, employers who would
lose federal contracting funding are exempt. Second, employees that use medical
cannabis or are impaired at work are exempt from employment protections.86
Notably, only Arizona provides a definition of “impairment” and contains certain
conditions that are not necessarily indicators of present cannabis impairment such
as smell and odor.87 Under Arizona law, an employer cannot be sued for taking
adverse action against a qualifying patient based on their “good faith belief” that
the employee was impaired by cannabis at work.88 It is clear, however, this
category of medical cannabis antidiscrimination statutes protect users from
termination because of a positive drug test. The same cannot be said for the
remaining statues.
The state of South Dakota will mandate beginning on July 1, 2021 that
medical cannabis users are afforded the same rights they would have under state
and local law if they were “pharmaceutical medication” users.89 This protection
for medical cannabis users includes “[a]ny interaction[s] with [their] employer[s]”

80 See

Stephen M. Scannell, Medical Marijuana and the ADA: Following the Path Blazed by State
Courts to Extend Protection, 12 ST. LOUIS U.J. HEALTH L. & POL’Y 391, 403-04 (2019).
81 Id. at 404.
82 N.Y. PUBLIC HEALTH LAW §3369(2) (McKinney 2021).
83 Lucía Morán, Emerging from the Smoke: Does an Employer Have A Duty to Accommodate an
Employee’s Medical Marijuana Use After Garcia v. Tractor Supply Company?, 48 N.M. L. REV.
194, 202 (2018).
84 §3369(2).
85 See Barreiro, supra note 14; V.A. Code § 54.1-3408.3 (2021).
86 Scannell, supra note 80 at 404-05.
87 See Kathleen Harvey, Protecting Medical Marijuana Users in the Workplace, 66 CASE W. RES.
L. REV. 209, 226 (2015).
88 See Whitmire v. Wal-Mart Stores Inc. 359 F. Supp.3d 761, 787 (D. Ariz. 2019).
89 S.D. Codified Laws § 34-20G-22 (2021).
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and “[d]rug testing by [their] employers.”90 While the South Dakota employment
protections seem to prohibit employers from specifically singling out medical
users, it carves out several exceptions. First, this protection does not apply if
federal law or regulations mandate adverse action for medical cannabis use.91
Second, the South Dakota law does not protect adverse action based on on-site or
working under the influence of cannabis.92 The law attempts to define “under the
influence” by stating medical cannabis users cannot be considered under the
influence “solely because of the presence of metabolites or components of
cannabis that appear in insufficient concentration to cause impairment.”93
The law’s subjective definition will likely cause employers confusion.94
This confusion will arise because the present methodology for cannabis testing is
not exact and is focused on testing for any past cannabis use instead of present
cannabis impairment.95 The root cause of this problem stems from the lack of
studies on cannabis’s effects on the body because of federal prohibition.96
However, some technologies are being researched to effectively test for present
cannabis impairment.97 Ultimately, the exception for adverse action based on
present cannabis impairment proven via testing is likely meaningless for South
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Id.

91 S.D. Codified Laws

§ 34-20G-23 (2021).
§ 34-20G-24 (2021).

92 S.D. CODIFIED LAWS
93 Id.
94 Rayna

H. Jones et al., Marijuana Ballot Initiatives Approved in Five States: What This Budding
Trend Means for Employers, OGLETREE DEAKINS (Nov. 11, 2020),
https://ogletree.com/insights/marijuana-ballot-initiatives-approved-in-five-states-what-thisbudding-trend-means-for-employers/.
95 See Ed Finkel, Ready or Not, Cannabis Is Here Will Unresolved Issues Spell Trouble for
Legalized Recreational Cannabis in Illinois?, 108 ILL. B.J. 24, 25 (2020); See also Matthew C.
Rappold, Criminal Law–Evidence of Inactive Drug Metabolites in Dui Cases: Using A Proximate
Cause Analysis to Fill the Evidentiary Gap Between Prior Drug Use and Driving Under the
Influence, 32 UALR L. REV. 535, 549 n. 128 (2010).
96 Spencer Gill, Budding Marijuana Industry Meets Climate & Environmental Crisis: A Call to
Legislative Action, 5 OIL & GAS, NAT. RES. & ENERGY J. 661, 686 (2020) (“Because marijuana
has been on the Schedule I list of controlled substances for the last fifty years, research concerning
marijuana's medicinal properties and effects or the plant's optimal growth cycle has been severally
inhibited because of the difficulty and potential legal liability associated with obtaining marijuana
for such studies.”); Katherine Berger, ABCs and CBD: Why Children with Treatment-Resistant
Conditions Should Be Able to Take Physician-Recommended Medical Marijuana at School, 80
OHIO ST. L.J. 309, 317 (2019) (“Because marijuana in most forms is federally illegal, little
accountable, large-scale research exists documenting medical marijuana's possible uses and
effects.”).
97 See e.g. Jena Hilliard, New Breathalyzer Can Now Detect Levels Of Marijuana, ADDICTION
CENTER (Sept. 13, 2019), https://www.addictioncenter.com/news/2019/09/new-breathalyzermarijuana/ (describing THC breathalyzer developed by a University of Pittsburgh research team);
Rebekah F. Ward, Impairment testing lags behind state cannabis legalization, TIMES UNION (May
11, 2021) (describing oral fluid device to test for cannabis consumption in the past twenty-four
hours).
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Dakota employers until drug testing technology evolves.98 Therefore, South
Dakota employers should not take adverse action based solely on a positive test
for cannabis or because the individual is a medical cannabis user.
The states of Connecticut, Illinois, Maine, New Jersey, Pennsylvania,
Rhode Island, and West Virginia protect an employee from adverse employment
action solely because of their status as a medical cannabis cardholder.99 In fact,
Illinois’ statue explicitly grants an employer the right to enforce drug tests so long
as they are not administered in a discriminatory fashion.100 Some commentators
interpret these laws to permit an employer to fire an employee because of a
positive test for cannabis without facing an employment discrimination claim.101
Several court decisions have disagreed with this view, holding these
statutes protect both the employee’s status as a medical cannabis cardholder and
from a positive drug test.102 These courts reason the statutory intent is to protect
an employee’s right to use medical cannabis.103 The remaining jurisdictions in this
category have not considered which interpretation they find more persuasive.
Two jurisdictions, Colorado and Oregon, have considered legislation
related to employment protections for therapeutic psilocybin users.104 Colorado
State Representative Jovan Melton introduced House Bill 1089 which “prohibits
an employer from terminating an employee” for “lawful off-duty activities,” even
if the activity is illegal under federal law.105 Melton proposed the law to overturn

98 See

generally What Measure 26 and Amendment A Mean for Employers, DAVENPORT EVANS
LAWYERS (Nov. 23, 2020), https://dehs.com/what-measure-26-and-amendment-a-mean-foremployers/ (opining new South Dakota medical cannabis employment protections are the same as
the status as cardholders and protection from a positive drug test for cannabis states until drug
testing technology evolves).
99 Barreiro, supra note 14.
100 410 Ill. Comp. Stat. Ann. 130/50 (2021).
101 E.g. Harvey, supra note 87 at 225; John McCreary Jr., Reprise of Employment Law Issues in
Pa.’s Medical Marijuana Act, LAW.COM THE LEGAL INTELLIGENCER, (Mar. 21, 2019, 2:49 PM),
https://www.law.com/thelegalintelligencer/2019/03/21/reprise-of-employment-law-issues-in-pa-smedical-marijuana-act/?slreturn=20200723085151.
102 Smith v. Jensen Fabricating Eng’rs, Inc., No. HHDCV186086419, 2019 Conn. Super. LEXIS
439, at *4 (Conn. Super. Ct. Mar. 4, 2019); Callaghan v. Darlington Fabrics Corp., No. PC-20145680, 2017 R.I. Super. LEXIS 88, at *16 (R.I. Super. Ct. May 23, 2017).
103 E.g., Callaghan, 2017 R.I. Super. LEXIS 88 at *16.
104 See generally Randy Robinson, Colorado Finally Files Bill to Protect Weed-Smoking
Employees, MERRY JANE (Jan. 15, 2020), https://merryjane.com/news/colorado-finally-files-billto-protect-weed-smoking-employees; see also Canna Law Blog, Will Oregon Finally Protect OffWork Marijuana Use in 2019?, HARRIS BRICKEN (Jan. 5, 2019),
https://harrisbricken.com/cannalawblog/will-oregon-finally-protect-off-work-marijuana-use-in2019/
105 Employee Protection Lawful Off-duty Activity, H.B. 1089, 72nd Gen. Assemb., 2d Reg. Sess.
(Colo. 2020); see Saja Hindi, Colorado lawmakers want to stop employers from firing people for
using weed in their personal time, THE DENVER POST (Jan. 19, 2020, 11:59 AM),
https://www.denverpost.com/2020/01/14/colorado-legislature-marijuana-employees-fired/.
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Coats v. Dish Network, LLC,106 where the Colorado Supreme Court held an
employer could fire an employee for using state sanctioned medical cannabis
because state law provided no statutory duty to accommodate medical cannabis
use.107 The proposed law would protect therapeutic psilocybin users if Colorado
legalized psilocybin statewide;108 a fact possibly forthcoming because Colorado
activists are pursuing a 2022 psilocybin ballot measure that would legalize
therapeutic psilocybin use.109
Despite this legislation’s trail-blazing attempt at providing psilocybin
users employment protections the bill as written has serious problems. First, the
legislation provides no exception for an employee that poses a direct threat to
either other employees, the public, or company property by forbidding an
employer from taking necessary safety action.110 It offers no exception for
compliance with federal law or federal contracting requirements; the lack of such
an exception would place employers in a difficult situation.111
Oregon Senator Floyd Prozanski took a similar approach like the proposed
Colorado law. The proposed Oregon law would overrule Emerald Steel, where the
Oregon Supreme Court refused to apply state antidiscrimination protections to a
disabled medical cannabis user.112 Senator Prozanski has proposed legislation
concerning employment protections for individuals who use substances legally
under state law but illegally under federal law twice -- in 2017 and 2019.113
Prozanski’s 2019 legislation forbid adverse action based solely on nonworking
hours use of a substance legal under state law (regardless of federal legality or
illegality).114 The legislation permits adverse action only if it relates to a bona fide
occupational qualification, on-site impairment, or permitted under a collective
bargaining agreement.115 Prozanski’s legislation is more complete compared to
Melton’s legislation because it forbids work-hours impairment and allows for
adverse action if it relates to a bona fide occupational qualification. However, the
106

Coats v. Dish Network, LLC, 350 P.3d 849, 853 (Colo. 2015).
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Id.
Robinson, supra note 104.
109 Kyle Jaeger, Colorado Activists Likely To Pursue 2022 Psilocybin Ballot Measure After Poll
Shows Support, MARIJUANA MOMENT (June 12, 2020),
https://www.marijuanamoment.net/colorado-activists-likely-to-pursue-2022-psilocybin-ballotmeasure-after-poll-shows-support/. A poll showed majority support for the proposed measure. Id.
110 See H.B. 1089.
111 See Id.
112 See Megan Vaniman, Oregon could learn from other states with employee protections for offwork medical marijuana use, CANNABIS L. J., https://journal.cannabislaw.report/oregon-couldlearn-from-other-states-with-employee-protections-for-off-work-medical-marijuana-use/.
113 Chris Miller, What’s Happening In The World Of Weed, THE SOURCE WKLY. (Mar. 20, 2019),
https://www.bendsource.com/bend/whats-happening-in-the-world-of-weed/Content?oid=9748506.
114 Relating to Unlawful Employment Practices; Prescribing an Effective Date, S.B. 301, 79th
Legis. Assemb. (Or. 2017).
115 Id.
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proposed Oregon law fails to create an exception for compliance with federal
contracting requirements.116 The lack of such an exception would put Oregon
contractors like their Colorado counterparts in an impossible situation regarding
compliance with federal contracting requirements and state antidiscrimination
law.117
B. THE TENSION BETWEEN FEDERAL AND STATE DRUG LAW IN EMPLOYMENT LAW
The simultaneous ban of all uses of psilocybin under federal law and
decriminalization in state and local laws creates tension in employment law.
Psilocybin’s illegality under the CSA prevents therapeutic psilocybin users from
protection under the ADA because it does not cover adverse action taken because
of illegal drug use.118
Perhaps an employee could argue their termination violates public policy
because the state legalized their therapeutic drug use.119 Two state courts have
considered a wrongful discharge for drug use on public policy grounds.120 In Ross
v. RagingWire Telecommunications, Inc., the California Supreme Court held
generally employment at will governs the employment relationship, but the rule is
subject to an exception that an employer may not discharge an employee for a
See Canna Law Blog, supra note 104.
E.g., Letter from Associated General Contractors Oregon Columbia Chapters to Chair
Prozanski and Members of the Committee (Feb. 20, 2017) available at
https://olis.oregonlegislature.gov/liz/2017r1/downloads/committeemeetingdocument/99340.
118 See 42 U.S.C. §§ 12111-14 (2018); Izzo v. Genesco, Inc., 171 F. Supp. 3d 1, 6 (D. Mass.
2016) (“[I]f an employee is terminated for illegal drug use, and he is in fact engaging in such use,
he does not qualify as disabled under the ADA. If an employee is not currently engaging in the
illegal use of drugs, however, but is erroneously regarded as engaging in such use, then he does
qualify for protection under the ADA.”); Nielsen v. Moroni Feed Co., 162 F.3d 604, 609 (10th
Cir. 1998) (“[U]nsatisfactory conduct caused by alcoholism and illegal drug use does not receive
protection under the ADA or the Rehabilitation Act.”); Laura L. Hirschfeld, Legal Drugs? Not
Without Legal Reform: The Impact of Drug Legalization on Employers Under Current Theories of
Enterprise Liability, 7 CORNELL J.L. & PUB. POL’Y 757, 834-35 (1998); Leslie Francis, Illegal
Substance Abuse and Protection from Discrimination in Housing and Employment: Reversing the
Exclusion of Illegal Substance Abuse as a Disability, 2019 UTAH L. REV. 891, 904 (2019) (“The
exclusion of current illegal drug use from the ADA definition of disability poses significant
problems for employees challenging adverse employment actions resulting from knowledge of
their substance use.”); Dale L. Deitchler & Wendy M. Krincek, Weed and Work: Are Marijuana
Users the Newest Protected Class?, NEV. LAW., February 2018, at 11 (“Accordingly, we believe
the ADA does not require that employers accommodate the use of medical marijuana by
employees…”).
119 See Dustin Stark, Just Say No: Foreclosing a Cause of Action for Employees Seeking
Reasonable Accommodation Under the New Jersey Compassionate Use Medical Marijuana Act,
43 SETON HALL L. REV. 409, 428-29 (2013) (arguing against public policy grounds litigation);
Kayla Goyette, Legalizing Marijuana: State and Federal Issue: Recreational Marijuana and
Employment: What Employees Don't Know Will Hurt Them, 50 GONZ. L. REV. 337, 341-42
(2014).
120 Sara E. Payne & Geoffrey A. Mort, Medical Marijuana in the Workplace: A Current Look at
Cannabis Law, N.Y. ST. B.J., July/Aug. 2018, at 8, 14.
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reason which violates a fundamental policy interest.121 To support such a cause of
action, the policy in question must: (1) be supported by either constitutional or
statutory provisions, (2) be public in the sense it benefits the public at large
instead of merely the interests of the individual, (3) have been articulated at the
time of the discharge, and (4) be “fundamental” and “substantial.”122
The court acknowledged that California did legalize medical cannabis use,
but the law did not speak to employment law.123 Additionally, the lack of
statutory language failed to put employers on notice.124 Therefore, the plaintiff
failed to state a cause of action for wrongful termination in violation of public
policy.125
The other state court that considered a public policy was the Washington
Supreme Court in Roe v. TeleTech Customer Care Mgmt. (Colorado) LLC. The
Supreme Court of Washington employed a similar analysis to Ross and held
because Washington state law provided no explicit employment protections for
medical cannabis users the termination did not violate public policy.126
Therefore, states must provide explicit statutory protections for therapeutic
psilocybin users to prevent adverse employment action.127
C. PREEMPTION CONCERNS
Even if a state were to enact an employment protection for therapeutic
psilocybin users it would likely be challenged on preemption grounds. Federal
law is “the supreme Law of the land” under the US Constitution’s Supremacy
Clause.128 The Supremacy Clause preempts state law that conflicts with federal
law and leaves the conflicting state law without effect and void.129 The Supreme
Court has recognized four types of preemption: express, field, conflict, and
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Compassionate Use of Medical Cannabis Pilot Program Act Does Not Provide Employees a Legal
Remedy for Adverse Action Based Upon Use in Compliance with the Statute, 49 J. MARSHALL L.
REV. 193, 201 (2015) (“The absence of any statutory protection for workplace discipline based
upon [medical cannabis] use is significant. Without [statutory] protection, registered users are
defenseless against discipline…”).
128 U.S. CONST. art. VI, cl. 2.
129 See, e.g., Lorillard Tobacco Co. v. Reilly, 533 U.S. 525, 540–53 (2001); Hughes v. Talen
Energy Mktg., LLC, 136 S. Ct. 1288, 1298 (2016).
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obstacle.130 First, express preemption occurs when a federal law contains a
provision forbidding state legislation on the topic.131 Second, field preemption
exists when the federal statute implies Congress has intended to occupy an entire
field and the states may not hinder federal law.132 Third, conflict preemption
occurs when it is impossible to comply with both federal and state law.133 Fourth,
obstacle preemption exists where compliance with state law frustrates the purpose
and effect of federal law.134
A state employment protection for therapeutic psilocybin users would
likely hinge on either conflict or obstacle preemption.135 No provision within the
CSA explicitly preempts state or local laws;136 therefore express preemption is
inapplicable. Field preemption is inapplicable too. After all, Section 903 of the
CSA declares, “No provision of this subchapter shall be construed as indicating
an intent on the part of the Congress to occupy the field.”137
The only two types of preemption that may apply to state or local
psilocybin laws are conflict and obstacle.138 Conflict preemption is a “rare
creature”139 and occurs when, “[The] conflict is so direct and positive that the two
acts cannot be reconciled or consistently stand together.”140 A hypothetical
example of conflict preemption regarding psilocybin would occur if a state law
130

Crosby v. Nat’l Foreign Trade Council, 530 U.S. 363, 372 n.6 (2000) (quoting English v. Gen.
Elec. Co., 496 U.S. 72, 79 n.5 (1990)).
131 E.g., Sprietsma v. Mercury Marine, a Div. of Brunswick Corp., 537 U.S. 51, 62-63 (2002).
132 E.g., Oneok, Inc. v. Learjet, Inc., 575 U.S. 373, 377 (2015).
133 E.g., Fla. Lime & Avocado Growers, Inc. v. Paul, 373 U.S. 132, 142 (1963).
134 E.g., Perez v. Campbell, 402 U.S. 637, 649 (1971).
135 See Robert J. Mikos, Preemption Under the Controlled Substances Act, 16 J. HEALTH CARE L.
& POL’Y 5, 15–17 (2013).
136 Connor P. Burns, I Was Gonna Get a Job, But Then I Got High: An Examination of Cannabis
and Employment in the Post-Barbuto Regime, 99 B.U. L. REV. 643, 652 (2019); Brandy M. Parry,
Puff, Puff, Pass: How State Marijuana Laws May Impact Probate Courts and Lead to Liability, 33
QUINNIPIAC PROB. L.J. 178, 188 (2020) (“[T]he CSA explicitly states that Congress did not intend
to preempt the field of marijuana law…”); John G. Sprankling, Owning Marijuana, 14 DUKE J.
CONST. L. & PUB. POL’Y 1, 21-22 (2019) (“Because no provision of the CSA expressly states that
it will supersede state law, there can be no express preemption.”).
137 21 U.S.C. § 903 (2018); Gonzales v. Oregon, 546 U.S. 243, 289 (2006) (Scalia J., dissenting)
(characterizing § 903 as a “nonpre-emption provision”); Luke C. Waters, Does Federal Law
Preempt State Marijuana Law? Analyzing the "Conflict", COLO. LAW., December 2018, at 34, 35
(“Congress not only excluded express preemption, but also made clear that it had no intent to
occupy the field; thus neither express nor field preemption is an issue when determining what
standard to apply in evaluating whether the CSA supersedes conflicting state laws.”).
138 Qualified Patients Ass’n v. City of Anaheim, 115 Cal. Rptr. 3d 89, 106 (Cal. Ct. App. 2010);
See generally Brannon P. Denning, State Legalization of Marijuana as a “Diagonal Federalism”
Problem, 11 FIU L. REV. 349, 353 (2016).
139 Robert S. Peck, A Separation-of-Powers Defense of the “Presumption Against Preemption”,
84 TUL. L. REV. 1185, 1193 (2010); See also Eang L. Ngov, Under Containment: Preempting
State Ebola Quarantine Regulations, 88 TEMP. L. REV. 1, 24 (2015) (“Because this type of
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165

required police officers return unlawfully seized psilocybin.141 This hypothetical
law is preempted under conflict preemption because the state law requires the
distribution of psilocybin which is illegal under the CSA.142 But neither state-level
decriminalization of therapeutic psilocybin nor employment protections for its
users conflict with the CSA because such laws do not require the possession of
psilocybin but rather only permit it.143
The strongest case for preemption in employment protections for
therapeutic psilocybin users lies with obstacle preemption.144 Obstacle preemption
arises when “under the circumstances of [a] particular case, [the offending state
law] stands as an obstacle to the accomplishment and execution of the full
purposes and objectives of Congress.”145 Whether obstacle preemption exists with
state employment protections for therapeutic psilocybin users depends on how the
state law is construed.146 State laws creating employment protections for
therapeutic psilocybin users could be viewed as enabling psilocybin use because
they make its consequences less severe.147 This interpretation would frustrate the
intent of the CSA to “conquer drug abuse.”148 On the other hand, one could
141

This hypothetical is based on a real case concerning cannabis distribution. See People v.
Crouse, 388 P.3d 39, 41 (Colo. 2017). A hotly debated area of conflict preemption is medical
cannabis and workers’ compensation. Jacob P. LaFreniere, A Bet Against Abetting: Why Medical
Marijuana Reimbursement Under Workers' Compensation Is Not a Federal Crime, 125 PENN ST.
L. REV. 223 (2020) (arguing employer reimbursement of medical cannabis is not illegal under the
CSA.). Courts have reached conflicting conclusions regarding whether the CSA preempts a
worker’s compensation order for an employer to pay for an employee’s medical cannabis.
Compare Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10 (Me. 2018) (holding CSA preempted
workers’ compensation order to reimburse employee’s medical cannabis because the employer
would knowingly assist in violating federal law), with Hager v. M & K Constr., 225 A.3d 137
(N.J. Super. Ct. App. Div. 2020) (holding ordering employer to cover medical cannabis costs
under workers’ compensation claim was not preempted by the CSA because it did not require the
company to possess, manufacture, or distribute cannabis), and Appeal of Panaggio, No. 20190685, 2021 WL 787021 at *1, *8 (N.H. Mar. 2, 2021) (same result).
142 Crouse, 388 P.3d at 41.
143 See Burns, supra note 136, at 652; Thomas R. Bender, State Medical Marijuana Laws, The
Federal Controlled Substances Act and Criminal Prosecutions, 63 RI BAR JNL., Nov./Dec. 2014,
at 13, 17 (“But, since state [therapeutic psilocybin] laws do not require [psilocybin] use, there are
no positive conflicting state and federal law requirements.”)
144 See Patricia J. Zettler, Pharmaceutical Federalism, 92 IND. L.J. 845, 880 (2017); See also
Michelle Patton, The Legalization of Marijuana: A Dead-end or the High Road to Fiscal
Solvency?, 15 BERKELEY J. CRIM. L. 163, 203 (2010).
145 Crosby v. Nat’l Foreign Trade Council, 530 U.S. 363, 373 (2000) (quoting Hines v.
Davidowitz, 312 U.S. 52, 67 (1941)).
146 See Burns, supra note 136, at 652-55.
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See generally Mikos, supra note 135, at 37; Michael A. Cole, Jr., Functional Preemption: An
Explanation of How State Medical Marijuana Laws Can Coexist with the Controlled Substances
Act, 16 MICH. ST. U. J. MED. & L. 557, 575 (2012) (“By enforcing private protections for
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148 Gonzales v. Raich, 545 U.S. 1, 12 (2005); Gonzalez v. Oregon, 546 U.S. 243, 246 (2006).
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interpret these employment protections as merely tolerating the employment of
therapeutic psilocybin users, and authorizing use of psilocybin offsite would not
frustrate the CSA’s intent.149 The latter viewpoint is bolstered by the fact there is
a presumption against preemption.150 The Supreme Court has warned lower courts
that obstacle preemption “does not justify a freewheeling judicial inquiry into
whether a state statute is in tension with federal objectives; [because] such an
endeavor would undercut the principle that it is Congress rather than the courts
that preempts state law.”151
The presumption against preemption is even stronger in areas where states
have traditionally occupied.152 The Supreme Court has held, “States possess broad
authority under their police powers to regulate the employment relationship to
protect workers within the State.”153 Despite this presumption courts have reached
conflicting holdings regarding employment protections for individuals using state
sanctioned medical/therapeutic drugs that remain federally illegal. The next
section surveys the split between the courts regarding preemption and argues that
courts finding no preemption present the stronger argument. Thus, an employer
who terminates a therapeutic psilocybin user solely because of a positive drug test
for psilocybin or due to their statute as a therapeutic psilocybin user likely
violates state law where a state has enacted an employment protection for users.
1. COURTS FINDING PREEMPTION?
Emerald Steel, a landmark case from the Oregon Supreme Court finding that
reading state antidiscrimination to include federally illegal drug users was
149

See Smith v. Jensen Fabricating Eng’rs, Inc., No. HHDCV186086419, 2019 Conn. Super.
LEXIS 439, at *1, *5–8 (Conn. Super. Ct. Mar. 4, 2019); James v. City of Costa Mesa, 700 F.3d
394, 412 (9th Cir. 2012).
150 Arizona v. Inter-Tribal Council of Ariz., Inc., 570 U.S. 1, 14 (2013); Egelhoff v. Egelhoff ex
rel. Breiner, 532 U.S. 141, 151 (2001).
151 Chamber of Com. of U.S. v. Whiting, 563 U.S. 582. 607 (2011) (quoting Gade v. Nat’l Solid
Wastes Mgmt. Assn., 505 U.S. 88, 111 (1992) (Kennedy, J., concurring)).
152 New York State Conference of Blue Cross & Blue Shield Plans v. Travelers Ins. Co., 514 U.S.
645, 655 (1995).(“[The presumption against preemption is heightened] where federal law is said to
bar state action in fields of traditional state regulation.”); California v. ARC America Corp.,490
U.S. 93, 101 (1989) (quoting Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947)) (“When
Congress legislates in a field traditionally occupied by the States, ‘we start with the assumption
that the historic police powers of the States were not to be superseded by the Federal Act unless
that was the clear and manifest purpose of Congress.’”); Pooja Nair, Wyeth v. Levine: Challenging
Implied Pre-emption for drugs, 37 J.L. MED. & ETHICS 527, 527 (2009) (“Unless there is clear
evidence of congressional intent to pre-empt state law, courts generally employ a presumption
against pre-emption, particularly in areas traditionally regulated by the states.”).
153 DeCanas v. Bica, 424 U.S. 351, 356 (1976); See also Lingle v. Norge Div. of Magic Chef,
Inc., 486 U.S. 399, 412 (1988) (quoting Fort Halifax Packing Co. v. Coyne, 482 U.S. 1, 21 (1987)
(“[P]re-emption should not be lightly inferred in this area, since the establishment of labor
standards falls within the traditional police power of the State.”); Chris Conrad, Reefer Access:
Dispensaries as "Places of Public Accommodation" Under Title III of the ADA, 108 Geo. L.J.
1331, 1360-61 (2020).
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preempted under obstacle preemption analysis.154 In Emerald Steel, an
anonymous temporary employee used medical cannabis to treat anxiety, panic
attacks, nausea, vomiting, and severe stomach cramps, all of which significantly
limited his ability to eat.155 On their own, the employee’s ailments qualified as a
“debilitating medical condition under Oregon law.156 Therefore, under state law
the employee was permitted to use medical cannabis.157
In 2002, the employee began using medical cannabis to treat his ailments per
physician recommendation.158 Shortly after beginning his medical cannabis use
the employee began work at Emerald Steel on a temporary basis as a drill press
operator.159 During this time, the employee used medical cannabis off-site and
during off-hours.160 Eventually, the employee approached his employer for fulltime employment and disclosed his medical cannabis use.161 In response, Emerald
Steel terminated the employee based solely on his state sanctioned cannabis
use.162
After his termination, the employee filed a complaint with the Oregon Bureau
of Labor and Industries (“BOLI”) alleging employment discrimination under
Oregon’s Employment Discrimination which prohibits discrimination against an
otherwise qualified person based on disability.163 BOLI investigated the
employee’s complaint and filed charges against Emerald Steel.164
The Oregon Supreme Court upheld the employee’s termination because ORS
659A.112 (Oregon’s antidiscrimination statute) did not protect users of “illegal
drugs.”165 Interpreting ORS 659A.112 to protect users of illegal drugs would
“authorize” cannabis use that is illegal under federal law.166 Despite Oregon
legalizing medical cannabis statewide federal law prohibited any form of cannabis
use.167 Therefore, the Supreme Court of Oregon upheld the employee’s
termination because he used federally illegal drugs.168
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Id. at 520.
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Emerald Steel is frequently cited for its preemption analysis and for the
proposition that state employment protections for drug users are preempted under
the CSA.169 However, there are reasons to think Emerald Steel is not an example
of federal preemption.170 In Emerald Steel, the Oregon Supreme Court only
considered a preemption argument to determine a statutory interpretation issue.171
Specifically, the Supreme Court of Oregon’s holding in Emerald Steel hinged on
ORS 659A.112’s exemption for employees using illegal drugs.172 This turned on
whether the plaintiff’s medical cannabis use was “authorized under … other
provisions of state or federal law.”173 At this point, the court held that to extent
Oregon law “authorized”174 plaintiff’s medical cannabis use was preempted
because such conduct would authorize “illegal drug use” and fell within ORS
659A.112’s statutory exception.175
ORS 659A.112’s exception for any “illegal use of drugs,” is significant. If
ORS 659A.112 did not contain a statutory exception for the “illegal use of drugs,”
the employee’s claim would likely have been able to proceed like in Barbuto v.
Advantage Sales & Mktg., LLC also concerning employment termination on the
169

E.g., Kayla M. Jacob, Reefer Madness: The Legal Quagmire of Medical Marijuana in the
Workplace, 47 S.U. L. REV. 423, 433-34 (2020); Helia Garrido Hull, Lost in the Weeds of Pot
Law: The Role of Legal Ethics in the Movement to Legalize Marijuana, 119 PENN ST. L. REV. 333,
345-46 (2014).
170 Burns, supra note 136 at 656; Scannell, supra note 80 at 412 (“[T]he Oregon Supreme Court
determined that Oregon's medical marijuana statute was preempted by the CSA. Why? Because
the Emerald Steel court was interpreting a medical marijuana statute that did not contain a
provision explicitly barring employment discrimination.”).
171 Noffsinger v. SSC Niantic Operating Co. LLC, 273 F. Supp.3d 326, 335 n.3 (D. Conn. 2017)
(“The decision in Emerald Steel turned on whether the plaintiff's use of medical marijuana
constituted ‘the use of illegal drugs,’ and therefore it turned on whether the use of medical
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172 OR. REV. STAT. § 659A.124(1) (2021).
173 OR. REV. STAT. § 659A.122(2) (2021) (defining “[i]llegal use of drugs” as “any use of drugs,
the possession or distribution of which is unlawful under state law or under the federal [CSA] ...
but does not include ... uses authorized ... under other provisions of state or federal law.”).
174 Emerald Steel’s authorization/decriminalization distinction logic has been criticized by both
courts and commentators. Emerald Steel Fabricators, Inc. v. Bureau of Lab. & Indus., 230 P.3d
518, 538–39 (Or. 2010) (Walters, J., dissenting) (criticizing the Emerald Steel majority’s
authorization analysis); White Mountain Health Ctr., Inc. v. Maricopa Cnty., 386 P.3d 416, 430
(Ariz. Ct. App. 2016) (“The authorization/decriminalization distinction itself seems to be
primarily semantic and ultimately results in a circular analysis.”); Daniel S. Korobkin et al.,
Distinguished Brief, John Ter Beek, Plaintiff-Appellee, v. City of Wyoming, Defendant-Appellant,
31 T.M. COOLEY L. REV. 293, 346 (“There is much to criticize in the [authorization analysis]
employed by the Emerald Steel majority…). Additionally, the Supreme Court of Oregon has since
tried to narrow Emerald Steel’s holding to the facts of its particular facts. See Ter Beek v. City of
Wyoming, 846 N.W.2d 531, 540 n.6 (Mich. 2014) (“[T]he Oregon Supreme Court has since
moderated [the affirmative authorization] aspect of its analysis, clarifying that ‘Emerald Steel
should not be construed as announcing a stand-alone rule that any state law that can be viewed as
‘affirmatively authorizing’ what federal law prohibits is preempted.’” (quoting Willis v. Winters,
253 P.3d 1058, 1064 n.6 (Or. 2011)); Burns, supra note 136, at 657.
175 Emerald Steel, 230 P.3d at 536.
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sole basis of off-site medical cannabis use.176 In Barbuto, Massachusetts general
law contained no exception for illegal use of drugs.177 Therefore, the Supreme
Court of Massachusetts allowed the plaintiff’s claim to proceed.178 Therefore, the
statutory language interpretation is significant in considering adverse employment
action against medical cannabis or therapeutic psilocybin users.
The preceding analysis highlights how statutory interpretation, and not
preemption, is the primary judicial methodology courts use to determine whether
an employee’s medical cannabis (or therapeutic psilocybin) use is protected under
state law.179
2. COURTS FINDING NO PREEMPTION
When considering explicit statutory employment protections for medical
cannabis users, five different courts have found such provisions are not preempted
by the CSA.180 This trend began in the summer of 2017 when the court in
Noffsinger v. SSC Niantic Operating Company, L.L.C., held Connecticut’s
employment protection for medical cannabis users was not preempted.181
In Noffsinger, the plaintiff was a registered medical cannabis
cardholder.182 She was offered employment at Bride Brook contingent on passing
a drug test.183 Noffsinger alerted her future employer she was a registered medical
cannabis user and used cannabis to treat post-traumatic stress disorder.184 After
Noffsinger’s drug test came back positive for cannabis, Bride Brook rescinded her
employment offer.185 In response, Noffsinger filed a complaint in federal court
alleging Bride Brook violated state law, Palliative Use of Marijuana Act
(“PUMA”), forbidding adverse action against a medical cannabis user’s status as
a cardholder.186
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The US District Court of Connecticut held the CSA did not preempt
PUMA for multiple reasons. The court rejected the defendant’s obstacle
preemption argument PUMA hindered the effect of federal law because the CSA
does not regulate employment practices nor does it forbid the employment of a
drug user.187 The Noffsinger court also held there is a presumption against
preemption and that courts should not extend a state law further than necessary to
create a conflict that leads to preemption.188 Therefore, the court held the
defendant violated PUMA by taking adverse employment action against
Noffsinger solely because of her status as a medical cannabis user.
Noffsinger’s significance should not be understated because it showcased
courts would uphold state employment protections for medical cannabis users.189
At bottom, employment protections for therapeutic psilocybin users are likely not
preempted under any species of preemption.
III.

STATUTE RECOMMENDATION

Because a hypothetical employment protection is likely not preempted,
states should enact employment protections for therapeutic psilocybin users.
Without the enactment of a statutory employment protection, what happened to
Rojerio Garcia would likely happen to many employees who uses therapeutic
psilocybin to treat mental illnesses.190 As a result, they would be forced to choose
between their medicine and employment.191 Those who suffer from serious
illnesses should not have to make this impossible choice. The statute presented in
this section addresses the rights of therapeutic psilocybin users. The following
section engages in statutory analysis.
187

Id. at 334.
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A. STATUTE LANGUAGE
State legislatures must have the foresight to include employment
protections in their therapeutic psilocybin statutes. In the medical cannabis
context, states that did not enact employment protections in their legalization
statutes failed to protect users from adverse employment action.192 Based on the
insights from case law and other states’ medical cannabis statutes, as states
legalize therapeutic psilocybin, I propose the following language be included in
psilocybin reform statues:
§ V. Employment Protections for Therapeutic Psychedelics
Users.
(a) Unless failure to do so would cause an employer to lose a
monetary or licensing-related benefit under federal law or
regulations, an employer may not discriminate against a person in
hiring, termination, or any condition of employment, or otherwise
penalize a person, based upon either:
(1) The person’s status as a state sanctioned therapeutic
psychedelic user; or
(2) A registered patient’s therapeutic use of a psychedelic, unless
the patient
used or possessed a psychedelic on company property during work
hours.
(b) Section (a) of this provision shall not protect a patient whose
therapeutic use of a psychedelic either:
(1) Poses a direct threat or danger to persons or property; or
(2) Prohibits the employee from fulfilling all of their job duties
(c) Employers shall be exempt from Section (a) to the extent
required to comply with state drug testing laws or regulations.
(d) Employers not exempt from Section (a) shall not be denied any
benefit for employing the persons identified in Sections (a)(1) and
(a)(2).
(e) Nothing in this section is intended to require an employer to
permit or accommodate the recreational use, sale, or possession of
any psychedelic drug in the workplace or to affect the ability of
employers to have policies restricting the use of recreational
psychedelics by employees.
192
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B. STATUTORY ANALYSIS
The first section describes who is protected and what actions constitute
employment discrimination against therapeutic psychedelic users. I deliberately
selected the word “psychedelic” instead of “psilocybin.” This word choice allows
for the statute to auto update and include other substances considered “classic
psychedelics”—psilocybin, lysergic acid diethylamide (“LSD”), N, Ndimethyltryptamine (“DMT”), ayahuasca, and mescaline (the peyote plant’s
active compound).193 If a state legalizes other classic psychedelics for therapeutic
use the legislature will not have to update the statute to provide employment
protections for users. For example, a 2016 English scientific study found LSD
treated depressive patients by enhancing feelings of openness, optimism, and
mood for about two weeks.194
This paper’s proposed statute opens with an exemption for employers that
would violate federal law such as Department of Transportation (“DOT”) and
Federal Railroad Administration (“FRA”) guidelines if they tolerated illegal drug
use in the workplace.195 This exemption protects both employers and insulates the
law from a preemption challenge.
This exception should be construed narrowly. Of particular importance to
employers, the exception largely does not apply to the federal Drug-Free
Workplace Act of 1988 (“DFWA”). The DFWA only requires federal contractors
make a good faith effort to “impose a drug-free workplace,” to remain eligible for
federal contracting funds.196 However, the DFWA does not mandate drug
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testing197 or adverse action based solely on a positive drug test.198 In fact, it does
not forbid the employment of a federally illegal drug user.199 Instead, the DFWA
is designed to only forbid the possession, sale, or use of federally illegal drugs at
the contractor’s worksite.200 Accordingly, a contractor does not violate the DFWA
by employing an off-site therapeutic psilocybin user.201 At bottom, the federal law
exception should be construed narrowly to apply only to DOT and FRA
regulations regarding mandatory drug testing.
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The statute then describes who is protected under the statute. It protects a
therapeutic psilocybin or psychedelic user from adverse action solely because of a
positive drug test or their status as a cardholder. But this statute goes further and
requires that an employee’s off-site psilocybin/psychedelic use pose a “direct
threat” to persons or property.
“Direct threat” tracks with the ADA provision that allows an employer to
take adverse action against prescription drug users if their use poses a direct threat
to others.202 Under the ADA, the direct threat assessment must be an
“individualized assessment of the individual's present ability to safely perform the
essential functions of the job.”203 The Supreme Court requires an “expressly
individualized assessment of the individual’s present ability to safely perform the
essential functions of the job,”204 Additionally, a speculative or slight risk does
not establish a direct threat exception.205 This expressly individualized assessment
should include consideration of the following factors: (1) the duration of the risk;
(2) the nature and severity of the potential harm; (3) the likelihood that the
potential harm will occur; and (4) the imminence of the potential harm.206
The direct threat framework balances the needs of employees and
employers. On one hand, an employee whose off-site and off-hours therapeutic
psychedelic use poses only a “slight or speculative risk” is protected under the
statute.207 However, the statute allows for some employer discretion if the
employee’s use would present a significant risk of harm.208 Under this proposed
202
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law, the on-site use or possession of a therapeutic psychedelic is prohibited. An
employer that knows an employee is impaired during work hours could
potentially be sued for negligence if the employee injures someone209 under the
doctrine of respondent superior.210 Other employees may not want to be around
someone who uses psilocybin, and an employer should be able to ensure
productivity and morale with anti-drug policies.211 These exceptions balance the
needs of the employer and the employee.
Section (c) ensures that the statute does not disregard mandatory state drug
testing requirements. Many states mandate drug testing for certain employees to
ensure workplace safety, the public welfare, and security.212 For example, Arizona
law requires vehicle for hire companies drug test their employees.213 Without this
section, employers face an impossible choice—violate the mandatory state drug
testing requirements or comply with therapeutic psychedelic user employment
protections.
Section (d) protects employers from discrimination based on employing
therapeutic psychedelic users. It ensures that statutory compliance will not create
any negative ramifications for the employer. Insurance companies could attempt
to encourage zero-tolerance drug testing policies by offering incentives to
employers that enforce them. With Section (d), an employer could not be denied
any benefit for refusing to take adverse action against an employee who uses
therapeutic psilocybin off-site and during off-hours.
IV.

CONCLUSION

No employee should have to choose between their medicine and their
career. In response to scientific studies showing psilocybin can treat major
depressive disorders such as postpartum depression states should enact
employment protections for therapeutic psilocybin users. Often when an
employee is known to both suffer from a mental illness and use psilocybin to treat
their condition, they risk being chastised by their coworkers or suffer adverse
209
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employment action.214 The statute in this paper lets therapeutic psilocybin users
(and potentially other therapeutic psychedelic users) avoid adverse employment
action based solely on their therapeutic drug use. The statute requires an employer
prove that the employee’s psilocybin use was a direct threat to workplace safety.
As Oregon regulators work to implement therapeutic psilocybin over the next two
years, the legislature should enact employment protections for therapeutic
psilocybin users. Additionally, as other states legalize therapeutic psilocybin,
they should not repeat the same mistakes that plagued medical cannabis
legalization.215 Instead, states can enact this paper’s proposed statute in tandem
with therapeutic psilocybin legalization to protect users from adverse action solely
for using state sanctioned medicine.

214
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Marks I, supra note 21 at 96.
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Appendix A
Psilocybin Reform
Jurisdictions216*
Therapeutic Use Legal

Lowest Law Enforcement Priority

Oregon

Denver, Colorado
Oakland, California
Santa Cruz, California
Ann Arbor, Michigan
Washington, D.C.
Somerville, Massachusetts
Cambridge,

Massachusetts

Northampton, Massachusetts

216* Margolin,

supra note 66; Kane, supra note 66.
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Appendix B
EMPLOYMENT PROTECTIONS FOR DRUG USERS217*
REASONABLE
MEDICAL
MEDICAL
MEDICAL
ACCOMMODATION CANNABIS USER CANNABIS
CANNABIS
IS CONSIDERED
USER’S
TREATED THE
HANDICAPPED
STATUS/
SAME AS
DRUG TEST PRESCRIPTION
PROTECTED
DRUG USER
ARIZONA SOUTH DAKOTA
NEVADA
NEW YORK
ARKANSAS
**** PAPER’S
DELAWARE
PROPOSED
MINNESOTA
PSYCHEDELIC
NEW MEXICO
STATUE
OKLAHOMA
VIRGINIA218**

217 *

MEDICAL
NO
CANNABIS
EMPLOYMENT
USER’S STATUS PROTECTIONS
IS PROTECTED

CONNECTICUT
ILLINOIS
MAINE
NEW JERSEY
PENNSYLVANIA
RHODE ISLAND
WEST VIRGINIA

See Barreiro, supra note 14; V.A. Code § 54.1-3408.3 (2021)
Only protects medical cannabis oil users. See id.
219***
No employment protections for therapeutic psilocybin or medical cannabis users.
218**
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ALABAMA
ALASKA
CALIFORNIA
COLORADO
FLORIDA
GEORGIA
HAWAII
MARYLAND
MICHIGAN
MONTANA
NEW
HAMPSHIRE
NORTH DAKOTA
OHIO
OREGON 219***
VERMONT
WASHINGTON

Appendix C
An Employer’s Reasonable
Accommodation Flow Chart

Employee Tests Positive for a
Psychedelic or is Discovered to be a
Therapeutic Psychedelic User

Is Employer Governed By DOT or
FRA Drug Testing?

NO
Individualized Assessment
Considering:
YES
Accommodation Not
Permitted

1) the duration of the risk; 2)
the nature and severity of the
potential harm; 3) the
likelihood that the potential
harm will occur; and 4) the
imminence of the potential
harm

Does Employee Pose a
“Direct Threat” to
Workplace Safety?

NO

YES

Accommodation
Permitted

Accommodation Not
Permitted
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